{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:21:04Z","timestamp":1788016864021,"version":"build-2784847793"},"reference-count":29,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":241,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Signal transducer and activator of transcription 3 (STAT3) is a signaling molecule that functions downstream of various cytokine and growth factor receptor signaling pathways to regulate cell growth, survival, and differentiation. Constitutive activation of STAT3 is relevant to cancer development and progression in many types of malignancies. In this study, the relationship between STAT3 activation and the prognosis of papillary thyroid carcinoma (PTC) was retrospectively examined using immunohistochemical staining with an anti-STAT3 antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 1,132 PTC cases with M0 diagnosed between 1993 and 2012 were included. The H-score (0\u2013300 points) was used to evaluate nuclear staining of STAT3 (n-STAT3), which reflects the activated form of STAT3. The relationship between the n-STAT3 score and recurrence-free survival (RFS) was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median n-STAT3 score was 105. RFS was compared between the two groups using the Kaplan\u2013Meier method at a cutoff of 70 points (AUC = 0.60), calculated from the ROC curve based on recurrence. Ten-year and 20-year RFS were 87.5 and 83.1% in the high n-STAT3 group (n = 764) and 77.7 and 72.6% in the low n-STAT3 group (n = 371), respectively. The high n-STAT3 group had a significantly better RFS (P &amp;lt; 0.0001). Age (\u226555 years), tumor size (\u22654 cm), extrathyroidal extension, larger maximum lymph node size (\u226530 mm), and low n-STAT3 levels were associated with poor RFS on univariate and multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>n-STAT3 scores in cases with PTC were associated with favorable prognosis. Further studies are required to elucidate the mechanism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0080","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:37:42Z","timestamp":1760708262000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":2,"title":["Nuclear STAT3 expression is associated with favorable prognosis in papillary thyroid carcinoma"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-6182","authenticated-orcid":true,"given":"Chie","family":"Masaki","sequence":"first","affiliation":[{"name":"1"},{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-9997","authenticated-orcid":true,"given":"Tomohiro","family":"Chiba","sequence":"additional","affiliation":[{"name":"1"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Baba","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Moriya","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ebina","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Toda","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mitani","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Jikuzono","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ohashi","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-9871","authenticated-orcid":true,"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwao","family":"Sugitani","sequence":"additional","affiliation":[{"name":"2"},{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026070714013870800_bib1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4158\/EP.14.6.764","article-title":"Risk-adapted management of thyroid cancer","volume":"14","author":"Tuttle","year":"2008","journal-title":"Endocr Pract"},{"key":"2026070714013870800_bib2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.surg.2014.08.060","article-title":"Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?","volume":"156","author":"Ebina","year":"2014","journal-title":"Surgery"},{"key":"2026070714013870800_bib3","first-page":"62","article-title":"Personalized treatment for differentiated thyroid cancer: current data and new perspectives","volume":"46","author":"Colombo","year":"2021","journal-title":"Minerva Endocrinol"},{"key":"2026070714013870800_bib4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3390\/cancers12082115","article-title":"TERT promoter mutation and extent of thyroidectomy in patients with 1\u20134 cm intrathyroidal papillary carcinoma","volume":"12","author":"Ebina","year":"2020","journal-title":"Cancers"},{"key":"2026070714013870800_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13048-021-00918-6","article-title":"The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis","volume":"14","author":"Gao","year":"2021","journal-title":"J Ovarian Res"},{"key":"2026070714013870800_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182282","article-title":"Correlation between p-STAT3 overexpression and prognosis in lung cancer: a systematic review and meta-analysis","volume":"12","author":"Tong","year":"2017","journal-title":"PLoS One"},{"key":"2026070714013870800_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160125","article-title":"The role of p-STAT3 as a prognostic and clinicopathological marker in colorectal cancer: a systematic review and meta-analysis","volume":"11","author":"Ji","year":"2016","journal-title":"PLoS One"},{"key":"2026070714013870800_bib8","first-page":"356","article-title":"Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer","volume":"4","author":"Zhang","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"2026070714013870800_bib9","doi-asserted-by":"crossref","first-page":"E2361","DOI":"10.1073\/pnas.1201232109","article-title":"STAT3 negatively regulates thyroid tumorigenesis","volume":"109","author":"Couto","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070714013870800_bib10","first-page":"413","article-title":"Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas","volume":"35","author":"Kim","year":"2012","journal-title":"J Endocrinol Investig"},{"key":"2026070714013870800_bib11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/1078-0432.CCR-06-2313","article-title":"Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications","volume":"13","author":"Huang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026070714013870800_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer \u2013 using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2026070714013870800_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1113\/expphysiol.1983.sp002748","article-title":"Immunocytochemistry and neurobiology","volume":"68","author":"Cuello","year":"1983","journal-title":"Q J Exp Physiol"},{"key":"2026070714013870800_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers6010526","article-title":"The role of STAT3 in thyroid cancer","volume":"6","author":"Sosonkina","year":"2014","journal-title":"Cancers"},{"key":"2026070714013870800_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070714013870800_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/cr.2008.18","article-title":"STAT3 as a target for inducing apoptosis in solid and hematological tumors","volume":"18","author":"Al Zaid Siddiquee","year":"2008","journal-title":"Cell Res"},{"key":"2026070714013870800_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","article-title":"The potential and controversy of targeting STAT family members in cancer","volume":"60","author":"Verhoeven","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2026070714013870800_bib18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/aging.100239","article-title":"STAT3, HIF-1, glucose addiction and Warburg effect","volume":"2","author":"Darnell","year":"2010","journal-title":"Aging"},{"key":"2026070714013870800_bib19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/cancers6020897","article-title":"STAT3 target genes relevant to human cancers","volume":"6","author":"Carpenter","year":"2014","journal-title":"Cancers"},{"key":"2026070714013870800_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/15384101.2016.1259037","article-title":"STAT3-mediated SMAD3 activation underlies oncostatin M-induced senescence","volume":"16","author":"Bryson","year":"2017","journal-title":"Cell Cycle"},{"key":"2026070714013870800_bib21","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1038\/ncomms8736","article-title":"STAT3 regulated ARF expression suppresses prostate cancer metastasis","volume":"6","author":"Pencik","year":"2015","journal-title":"Nat Commun"},{"key":"2026070714013870800_bib22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/iub.2056","article-title":"TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower (131) i uptake in metastases","volume":"71","author":"Meng","year":"2019","journal-title":"IUBMB Life"},{"key":"2026070714013870800_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"key":"2026070714013870800_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/thy.2015.0391","article-title":"BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis","volume":"26","author":"Chen","year":"2016","journal-title":"Thyroid"},{"key":"2026070714013870800_bib25","doi-asserted-by":"crossref","first-page":"15626","DOI":"10.3390\/ijms232415626","article-title":"Association of BRAF(V600E) mutation with the aggressive behavior of papillary thyroid microcarcinoma: a meta-analysis of 33 studies","volume":"23","author":"Attia","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026070714013870800_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1507\/endocrj.K08E-208","article-title":"BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients","volume":"56","author":"Ito","year":"2009","journal-title":"Endocr J"},{"key":"2026070714013870800_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep41752","article-title":"TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors","volume":"7","author":"Matsuse","year":"2017","journal-title":"Sci Rep"},{"key":"2026070714013870800_bib28","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.21037\/gs-20-430","article-title":"Prevalence of BRAF(V600E) mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review","volume":"9","author":"Rashid","year":"2020","journal-title":"Gland Surg"},{"key":"2026070714013870800_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00394-016-1370-2","article-title":"Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area","volume":"57","author":"Kim","year":"2018","journal-title":"Eur J Nutr"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/6\/ETJ-25-0080.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/6\/ETJ-25-0080.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0080\/506963\/etj-25-0080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0080\/506963\/etj-25-0080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:48Z","timestamp":1783447308000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/6\/e250080\/75663\/Nuclear-STAT3-expression-is-associated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0080","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"e250080"}}